2nd peer-review confirms excellent performance of PainChek
Filed with ASX · · 2 pages · English
Earlier from PainChek
- ePAT and PainChek continue to achieve commercial milestones
- Placement to raise $3.75 million
- Core strategic agreement with Dementia Support Australia
- ePAT Clinical Study Published in Alzheimers Disease Journal
- nViso agrees perpetual global license, takes strategic stake
Later from PainChek
- New Peer reviewed published study
- PainChek App Android version now in beta testing
- Half Year Report and Financial Statements
- Agreement signed with leading software system provider
- PainChek receives FDA regulatory guidance
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek